Rahul Kakkar, Tome Biosciences CEO

MIT gene edit­ing spin­out launch­es with $213M to write the 'fi­nal chap­ter in ge­nom­ic med­i­cine'

When John Finn agreed to meet two young MIT sci­en­tists in the sum­mer of 2021, they ex­plained how they had de­vel­oped a twist on CRISPR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.